Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide

Anti-Cancer Drugs

Volumn 9, Issue 9, 1998, Pages 751-757

  Breton, Christel ^a   Story, Michael D ^a   Meyn, Raymond E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Etoposide; Small cell lung cancer; Thiols

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOSIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLONOGENIC ASSAY; ONCOGENE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, SMALL CELL; CELL SURVIVAL; CULTURE MEDIA; CYSTINE; ETOPOSIDE; GENE EXPRESSION; GENES, BCL-2; HUMANS; LUNG NEOPLASMS; METHIONINE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0031762429     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199810000-00002     Document Type: Article

References (32)

1. Bunn PA. Current therapy for small cell lung cancer. Semin Oncol 1996; 23: 1-2.
2. Postmus PE, Scagliotti G, Groen HJM, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial. Eur J Cancer 1996; 32A: 1498-503.
3. Smets L. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs 1994; 5: 3-9.
4. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
5. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845-53.
6. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-42.
7. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
8. Jacobson MD, Burne JF, King MP, et al. Apoptosis and bcl-2 protein in cells without mitochondrial DNA. Nature 1993; 361: 365-9.
9. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bel-2. Biochem Biophys Res Commun 1993; 192: 30-6.
10. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am 1995; 9: 451-73.
11. Ikegaki N, Katsumata M, Minna J, et al. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8.
12. Higashiyama M, Doi O, Kodama K, et al. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 1995; 15: 503-5.
13. Yang E and Korsmeyer SJ. Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 1996; 88: 386-401.
14. Hockenbery DM, Oltvai ZN, Yin X-M, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-51.
15. Kane DJ, Sarafian TA, Anton R, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-7.
16. Mirkovic N, Voehringer D, Story M, et al. Resistance to radiation-induced apoptosis in bcl-2 expressing cells is reversed by depleting cellular thiols. Oncogene 1997; 15: 1461-70.
17. Voehringer DW, McConkey DJ, McDonnell TJ, Brisbay S, Meyn RE. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc Natl Acad Sci USA 1998; 95: 2956-60.
18. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913-23.
19. Dynlacht JR, Henthorn J, O'Nan C, et al. Flow cytometric analysis of nuclear matrix proteins: method and potential applications. Cytometry 1996; 24: 348-59.
20. Hissin PJ, Hilf RA. Fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976; 74: 214-26.
21. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-7.
22. Strasser A, Harris A, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by bcl-2. Cell 1994; 74: 329-39.
23. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-6.
24. Yin DX, Schimke RT. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 1995; 55: 4922-8.
25. Lock RB, Stribinskiene L. Dual modes of death induced in human epithelial tumor cells allow bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996; 56: 4006-12.
26. Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology 1997; 11: 349-65.
27. Domen J, Gandy KL, Weissman IL. Systemic overexpression of bcl-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998; 91: 2272-82.
28. Brunet CL, Gunby RH, Benson RSP, Hickman JA, Watson AJM, Brady G. Committment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Different 1998; 5: 107-15.
29. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth bcl2. Cancer Res 1994; 54: 3714-7.
30. O'Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol 1997; 159: 2301-11.
31. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3: 1034-6.
32. Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997; 57: 4703-6.